Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 403

1.

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Graham J, Wells JC, Donskov F, Lee JL, Fraccon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, Choueiri TK, Heng DYC.

Eur Urol Oncol. 2019 Apr 4. pii: S2588-9311(19)30041-0. doi: 10.1016/j.euo.2019.03.007. [Epub ahead of print]

PMID:
31411994
2.

Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer.

Kim HS, Koom WS, Baek SE, Kim HI, Jung M, Beom SH, Kang B, Kim H, Chang JS, Choi YY, Son T, Cheong JH, Noh SH, Kim EH, Park JC, Shin SK, Lee SK, Lee YC, Shin SJ, Chung H, Jung I, Chung HC, Lim JS, Hyung WJ, Rha SY.

Radiother Oncol. 2019 Jul 11;140:143-149. doi: 10.1016/j.radonc.2019.06.029. [Epub ahead of print]

PMID:
31302344
3.

Unmet needs in the physical and daily living domain mediates the influence of symptom experience on the quality of life of gastric cancer patients.

Rha SY, Lee HJ, Lee J.

Support Care Cancer. 2019 Jul 2. doi: 10.1007/s00520-019-04954-3. [Epub ahead of print]

PMID:
31267280
4.

Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using ¹⁸F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma.

Chun YJ, Jeung HC, Park HS, Park JS, Rha SY, Choi HJ, Lee JH, Jeon TJ.

Yonsei Med J. 2019 Jul;60(7):604-610. doi: 10.3349/ymj.2019.60.7.604.

5.

Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients.

Kwon JH, Lee SC, Lee MA, Kim YJ, Kang JH, Kim JY, Lee HJ, Bae WK, Kim MJ, Chie EK, Kim J, Kim YH, Chung HC, Rha SY.

Cancer Res Treat. 2019 Jul;51(3):851-860. doi: 10.4143/crt.2019.137. Epub 2019 Jun 7.

6.

Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LifE (SMILE)-a randomized controlled trial.

Rha SY, Nam JM, Lee J.

Support Care Cancer. 2019 May 25. doi: 10.1007/s00520-019-04865-3. [Epub ahead of print]

PMID:
31129760
8.

Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer.

Jung M, Park KH, Kim HM, Kim TS, Zhang X, Park SM, Beom SH, Kim HS, Cheong JH, Chung HC, Soong J, Lin SC, Rha SY.

Gastric Cancer. 2019 May 16. doi: 10.1007/s10120-019-00971-7. [Epub ahead of print]

PMID:
31098863
9.

Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer.

Shin SJ, Park S, Kim MH, Nam CM, Kim H, Choi YY, Jung MK, Choi HJ, Rha SY, Chung HC.

Oncologist. 2019 Apr 23. pii: theoncologist.2018-0896. doi: 10.1634/theoncologist.2018-0896. [Epub ahead of print]

PMID:
31015316
10.

Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma.

Lee JB, Park HS, Park S, Lee HJ, Kwon KA, Choi YJ, Kim YJ, Nam CM, Cho NH, Kang B, Chung HC, Rha SY.

Cancer Res Treat. 2019 Oct;51(4):1578-1588. doi: 10.4143/crt.2018.671. Epub 2019 Apr 16.

11.

A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer.

Kim TY, Han HS, Lee KW, Zang DY, Rha SY, Park YI, Kim JS, Lee KH, Park SH, Song EK, Jung SA, Lee N, Kim YH, Cho JY, Bang YJ.

Gastric Cancer. 2019 Apr 3. doi: 10.1007/s10120-019-00958-4. [Epub ahead of print]

PMID:
30945121
12.

Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.

Kim C, Chon HJ, Kim JH, Jung M, Nam CM, Kim HS, Kang B, Chung HC, Rha SY.

Eur J Cancer. 2019 May;112:20-28. doi: 10.1016/j.ejca.2018.11.029. Epub 2019 Mar 19.

PMID:
30901609
13.

Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea.

Kim HS, Nam CM, Jang SY, Choi SK, Han M, Kim S, Moneta MV, Lee SY, Cho JM, Novick D, Rha SY.

Cancer Res Treat. 2019 Oct;51(4):1380-1391. doi: 10.4143/crt.2018.476. Epub 2019 Feb 18.

14.

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.

J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1.

15.

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ.

Future Oncol. 2019 Mar;15(9):929-941. doi: 10.2217/fon-2018-0745. Epub 2019 Jan 28.

16.

Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition.

Lee SH, Lee WK, Kim N, Kang JH, Kim KH, Kim SG, Lee JS, Lee S, Lee J, Joo J, Kwon WS, Rha SY, Kim SY.

Cancers (Basel). 2018 Nov 19;10(11). pii: E455. doi: 10.3390/cancers10110455.

17.

Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy.

Beom SH, Choi YY, Baek SE, Li SX, Lim JS, Son T, Kim HI, Cheong JH, Hyung WJ, Choi SH, Jung M, Kim HS, Jeung HC, Chung HC, Rha SY, Noh SH.

BMC Cancer. 2018 Nov 15;18(1):1116. doi: 10.1186/s12885-018-4998-x.

18.

Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.

Kim HM, Jeong I, Kim HJ, Kang SK, Kwon WS, Kim TS, Park KH, Jung M, Soong J, Lin SC, Chung HC, Rha SY.

Anticancer Res. 2018 Nov;38(11):6171-6180. doi: 10.21873/anticanres.12970.

PMID:
30396934
19.

Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.

Kim JH, Park HS, Heo SJ, Kim SK, Han JW, Shin KH, Kim SH, Hur H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim HS.

Oncology. 2019;96(2):59-69. doi: 10.1159/000492597. Epub 2018 Oct 18.

PMID:
30336470
20.

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.

Kim SH, Ryu H, Ock CY, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Bang SM, Kim JH, Lee JS, Ahn JB, Kim KJ, Rha SY.

Int J Mol Sci. 2018 Oct 15;19(10). pii: E3164. doi: 10.3390/ijms19103164.

21.

Reconsideration of sample size and power calculation for overall survival in cancer clinical trials.

Jung I, Ko HJ, Rha SY, Nam CM.

Contemp Clin Trials Commun. 2018 Sep 28;12:90-91. doi: 10.1016/j.conctc.2018.09.007. eCollection 2018 Dec.

22.

Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial.

Kim MH, Zhang X, Jung M, Jung I, Park HS, Beom SH, Kim HS, Rha SY, Kim H, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung HC.

Cancer Res Treat. 2019 Apr;51(2):819-831. doi: 10.4143/crt.2018.331. Epub 2018 Sep 27.

23.

Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer.

Jeong I, Kang SK, Kwon WS, Kim HJ, Kim KH, Kim HM, Lee A, Lee SK, Bogenrieder T, Chung HC, Rha SY.

J Cell Mol Med. 2018 Dec;22(12):5899-5908. doi: 10.1111/jcmm.13859. Epub 2018 Sep 24.

24.

Author Correction: Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin.

Jeong BY, Cho KH, Jeong KJ, Park YY, Kim JM, Rha SY, Park CG, Mills GB, Cheong JH, Lee HY.

Exp Mol Med. 2018 Sep 19;50(9):124. doi: 10.1038/s12276-018-0148-4.

25.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.

Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M, Grande E, Suarez C, Markby DW, Arroyo A, Dean M, Choueiri TK, George D.

Br J Cancer. 2018 Sep;119(6):663-669. doi: 10.1038/s41416-018-0164-0. Epub 2018 Sep 10.

26.

Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy.

Rha SY, Park M, Lee J.

Support Care Cancer. 2019 May;27(5):1687-1695. doi: 10.1007/s00520-018-4413-9. Epub 2018 Aug 17.

PMID:
30120557
27.

Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.

Park HS, Kim HS, Beom SH, Rha SY, Chung HC, Kim JH, Chun YJ, Lee SW, Choe EA, Heo SJ, Noh SH, Hyung WJ, Cheong JH, Kim HI, Son T, Lim JS, Baek SE, Jung M.

Ann Surg Oncol. 2018 Oct;25(11):3222-3230. doi: 10.1245/s10434-018-6624-1. Epub 2018 Jul 26.

PMID:
30051367
28.

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.

Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR, Sundar R, So JB, Shabbir A, Tan CS, Kim HS, Jung M, Chung HC, Ng MCH, Tai DW, Lee MH, Wu J, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium (SGCC).

Clin Cancer Res. 2018 Nov 1;24(21):5272-5281. doi: 10.1158/1078-0432.CCR-18-0193. Epub 2018 Jul 25.

PMID:
30045931
29.

The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer.

Chon HJ, Kim C, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, Rha SY.

Gastric Cancer. 2019 Jan;22(1):113-122. doi: 10.1007/s10120-018-0847-5. Epub 2018 Jun 9.

30.

CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer.

Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, Rha SY, Ahn JB.

Yonsei Med J. 2018 Jul;59(5):588-594. doi: 10.3349/ymj.2018.59.5.588.

31.

A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy.

Chae D, Nam CM, Kim JH, Lee CK, Kim SS, Kim HS, Jung M, Cheong JH, Chung HC, Rha SY, Park K.

AAPS J. 2018 May 29;20(4):72. doi: 10.1208/s12248-018-0223-8.

PMID:
29845329
32.

MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.

Kim HS, Chon HJ, Kim H, Shin SJ, Wacheck V, Gruver AM, Kim JS, Rha SY, Chung HC.

J Surg Oncol. 2018 Jun;117(8):1679-1686. doi: 10.1002/jso.25097. Epub 2018 May 22.

PMID:
29790169
33.

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.

Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R.

J Hematol Oncol. 2018 May 22;11(1):69. doi: 10.1186/s13045-018-0617-1.

34.

'Screening audit' as a quality assurance tool in good clinical practice compliant research environments.

Park S, Nam CM, Park S, Noh YH, Ahn CR, Yu WS, Kim BK, Kim SM, Kim JS, Rha SY.

BMC Med Ethics. 2018 Apr 25;19(1):30. doi: 10.1186/s12910-018-0269-2.

35.

Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.

Lee SH, Lee B, Shim JH, Lee KW, Yun JW, Kim SY, Kim TY, Kim YH, Ko YH, Chung HC, Yu CS, Lee J, Rha SY, Kim TW, Jung KH, Im SA, Moon HG, Cho S, Kang JH, Kim J, Kim SK, Ryu HS, Ha SY, Kim JI, Chung YJ, Kim C, Kim HL, Park WY, Noh DY, Park K.

Cancer Res Treat. 2019 Jan;51(1):211-222. doi: 10.4143/crt.2018.132. Epub 2018 Apr 23.

36.

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.

Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP.

BMC Cancer. 2018 Mar 27;18(1):332. doi: 10.1186/s12885-018-4234-8.

37.

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.

Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YI, Park SR, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC.

Ann Oncol. 2018 May 1;29(5):1220-1226. doi: 10.1093/annonc/mdy055.

PMID:
29438463
38.

Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.

Kim HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, Rha SY.

Int J Cancer. 2018 Jul 1;143(1):151-159. doi: 10.1002/ijc.31304. Epub 2018 Feb 23.

39.

Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).

Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK.

Gastric Cancer. 2018 Sep;21(5):819-830. doi: 10.1007/s10120-018-0806-1. Epub 2018 Feb 9.

PMID:
29427038
40.

Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.

Cho YJ, Kim SH, Kim EK, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Jung ST, Kim HS.

BMC Cancer. 2018 Feb 7;18(1):158. doi: 10.1186/s12885-018-4066-6.

41.

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.

Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY.

Cancer Res Treat. 2019 Jan;51(1):1-11. doi: 10.4143/crt.2018.028. Epub 2018 Feb 5.

42.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ.

Ann Oncol. 2018 Nov 1;29(11):2269. doi: 10.1093/annonc/mdx807. No abstract available.

43.

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11.

Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK.

Gastric Cancer. 2018 Sep;21(5):802-810. doi: 10.1007/s10120-018-0794-1. Epub 2018 Jan 25.

PMID:
29372461
44.

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.

Kim C, Lee CK, Chon HJ, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, Rha SY.

Oncotarget. 2017 Dec 9;8(69):113494-113501. doi: 10.18632/oncotarget.23054. eCollection 2017 Dec 26.

45.

Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin.

Jeong BY, Cho KH, Jeong KJ, Park YY, Kim JM, Rha SY, Park CG, Mills GB, Cheong JH, Lee HY.

Exp Mol Med. 2018 Jan 26;50(1):e435. doi: 10.1038/emm.2017.248. Erratum in: Exp Mol Med. 2018 Sep 19;50(9):124.

46.

Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.

Lee SH, Kim JE, Jang HS, Park KH, Oh BH, Shin SJ, Chung KY, Roh MR, Rha SY.

Cancer Res Treat. 2018 Oct;50(4):1378-1387. doi: 10.4143/crt.2017.535. Epub 2018 Jan 22.

47.

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N.

Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2.

PMID:
29103871
48.

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer.

Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, Park HS, Heo SJ, Beom SH, Kim HS, Rha SY, Chung HC, Kang SM, Jung M.

Oncotarget. 2017 Jun 27;8(37):61837-61845. doi: 10.18632/oncotarget.18700. eCollection 2017 Sep 22.

49.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T.

Ann Oncol. 2017 Nov 1;28(11):2754-2760. doi: 10.1093/annonc/mdx493.

PMID:
28950297
50.

Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.

Jeung HC, Rha SY, Shin SJ, Ahn JB, Park KH, Kim TS, Kim JJ, Roh JK, Chung HC.

Oncol Lett. 2017 Aug;14(2):2385-2392. doi: 10.3892/ol.2017.6438. Epub 2017 Jun 21.

Supplemental Content

Support Center